Landauer Inc

Landauer — Investor Presentation (May 2017)

24 slides from Landauer's investor presentation, May 10, 2017

  1. Slide 1: Investor Presentation May 2017

    Investor Presentation May 2017

  2. Slide 2: Forward-looking statements

    Some of the information shared here (including, in particular, the section titled “Fiscal Year 2017 Outlook ”) constitutes forward-looking statements that are based on assumptions and involve certain risks and uncertainties. These include the following, without limitation: assumptions, risks and unc

  3. Slide 3: Global Leader in Occupational Radiation Products and Services

    •The Joint Commission standards effective in July 2015 in the United States -Impacts 7,100 of the 20,500 U.S. healthcare organiz ations and programs, including hospitals, imaging clinics and certain ambulatory care centers-Estimated incremental cost of ~$30,000 annually for a hospital to comply with

  4. Slide 4: OSL technology and monthly dosimetry process

    .“Gold standard” in accuracy .Proprietary OSL crystal technology manufactured internally.Delivers wide-range of radiation monitoring:Dosimetry Reports with results are made available to the customer .Headquartered in Glenwood, IL.650 global employees.Only national network of imaging physicists.8 glo

  5. Slide 5: Serving Diverse End Markets Across Three Verticals

    ProfessionalOfficesServing Diverse End Markets Across Three VerticalsAcute Care HospitalsProfessional OfficesIndustrialEnergyEmergency ResponseMilitary/National Security/DOEW:\Landauer\Investors\Investor deck\Images\73470968_5.jpgW:\Landauer\Investors\Investor deck\Images\L41513.2429.jpgPhysician Of

  6. Slide 6: Global service labs serving ~75,000 clients

    Service LabsWell-positioned to serve an expanding global customer base of ~75,000 clients ChicagoMexicoBrazilParisIstanb u l Beijing TokyoAustralia

  7. Slide 7: Revenue split and international joint ventures

    Additional $1.5 million in Equity Income from International Joint Ventures80%20%FY GAAP 2016 RevenueDomestic U.S.InternationalJoint VentureLocationNagase-LANDAUERJapanEpsilon LANDAUERTurkeyAquilaNew MexicoEstimated 25% international market share provides ample room for continued growth

  8. Slide 8: U.S. Healthcare Trends are Fueling Opportunity

    U.S. Healthcare Trends are Fueling OpportunityIncreasingly complex and multi-dimensional radiation management landscape creates need for integrated, enterprise-wide solutions Tougher State Regulations Emerging•Pennsylvania•California•Massachusetts•Rhode Island•TexasHealthcare Consolidation•Larger bu

  9. Slide 9: Uniquely Positioned to Capitalize on Demand for Solutions

    Reports:Necessary for complianceAnalytics:Context to informationBenchmarking:Relevance to peersTraining:Assures compliance and patient outcomesContinuous Improvement:Integrated data across the enterpriseUniquely Positioned to Capitalize on Demand for SolutionsCombining products, services, data and a

  10. Slide 10: Connect, Integrate, Expand: Beyond Dose

    .Shift the market focus .Simple dose focus .Continuous management of radiation safety.Better equip customers to monitor and control employee exposure and meet increasing compliance regulations.Leverage digital-based platform to grow offering of tailored products and services designed to better conne

  11. Slide 11: Verifii digital platform

    .Provides customers with a scalable, digital platform that connects employees to their environment .Eliminates fragmented manual processes enabling focus on building a robust radiation management solution.Timely radiation data adds value to customers by allowing them to take targeted actions for pra

  12. Slide 12: How Verifii works

    Real-time and historic data & analytics are available to client via web & mobile appsAllows customers to track trends, monitor event specific dose levels and enact behavioral changes to better manage long-term exposure Data is processed and stored in the cloudDosimeter connects via Bluetooth LE to d

  13. Slide 13: Growth opportunities by vertical

    .Virtual compliance solution for smaller offices that do not have an existing function in place.340,000 sites across Veterinarians, Medical, Dental and Chiropractic practices.6% estimated U.S. market share.Increasing regulations and use of advanced imaging equipment driving need for radiation safety

  14. Slide 14: Capital allocation: invest, pay down debt, fund dividend

    .Core business investments focused on top and bottom line growth.Emphasis on higher margin, annuity-style opportunities.Commercialization of next generation digital dosimetry platform while transitioning from current OSL crystal-based platform.Management compensation tied to ROIC.Long-term target of

  15. Slide 15: Investment highlights

    •The Joint Commission standards effective in July 2015 in the United States -Impacts 7,100 of the 20,500 U.S. healthcare organizations and programs, including hospitals, i maging clinics and certain ambulatory care centers-Estimated incremental cost of ~$30,000 annually for a hospital to comply with

  16. Slide 16: Financial Overview

    LANDAUER*® Financial Overview

  17. Slide 17: Revenue history and recurring revenue

    .Approximately 90% of revenue derived from subscriptions and is recurring in nature.2016 Revenues of $149.2 million impacted by 2015 Radon divestiture and 2016 Medical Products divestiture; pro forma 2016 revenues increased 4.8%.Contract with U.S. Army, Reserve and National Guard to replace its anti

  18. Slide 18: Key Q2 FY 2017 Financial Drivers

    $38.1Key Q2 FY 2017 Financial Drivers•Revenue of $39.1 million in the second quarter of fiscal 2017 includes ($2.5 million) impact of our divested Medical Products business•Military product sales increased $2.9 million compared to the prior year due to timing of shipments•Medical Physics revenues gr

  19. Slide 19: Q2 comparable results excluding divestiture

    * Non-GAAP financial measure($ Millions)Q2 FY2017As ReportedQ2 FY2017 Medical Products AdjustmentQ2 FY2017 Comparable, Excluding Divestiture*Revenue$39.1$ -$39.1Operating Income$7.8$ -$7.8($ Millions)Q2 FY2016As ReportedQ2 FY2016 Medical Products AdjustmentQ2 FY2016 Comparable, Excluding Divestiture

  20. Slide 20: FY2016 and FY2015 comparable results

    * Non-GAAP financial measure($ Millions)FY2016As ReportedFY2016 Medical Products AdjustmentFY2016 Radon AdjustmentFY2016 Comparable, Excluding Divestitures *Revenue$149.2$(5.8)$(0.1)$143.3Operating Income$26.6$(1.0)$(0.1)$25.5($ Millions)FY2015As ReportedFY2015 Medical Products AdjustmentFY2015 Rado

  21. Slide 21: Fiscal Year 2017 Outlook

    *Non-GAAP financial measure.In FY2017, we expect additional R&D spending and marketing and operations expenses of approximately $2 million to support the next generation Verifiiplatform launch.Fiscal Year 2017 Outlook($ Millions)FY 2016 ActualImpact of DivestedBusiness, Gain on Divestiture and Other

  22. Slide 22: Appendix

    LANDAUER*® Appendix

  23. Slide 23: Business facts and fiscal 2016 highlights

    IDN HospitalsBusiness FactsProven Technology PlatformFiscal 2016 Financial HighlightsDiverse Markets.$149.2 Million in Annual Revenue .$28.9 Million in International Sales.~ 90% Recurring Revenues.$41.2 Million in Adjusted EBITDA .Adjusted EBITDA margin 27.6%.Headquartered in Glenwood, IL.Founded in

  24. Slide 24: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures Management believes the disclosure of certain non-GAAP financial measures enhances investor understanding of our financial performance. Non-GAAP financial measures disclosed in this report include: Pro Forma Revenue and Pro Forma Operating Income. The Pro Forma Rev

Landauer — Investor Presentation (May 2017) on 6ix